Adding filtering to improve donor lungs
Part of Lungs & breathing clinical trials.
This trial tests whether adding a special filtering treatment (hemodiafiltration) during the lung reconditioning process (EVLP) can help improve marginal donor lungs before transplant. It aims to see if more lungs can be used for patients waiting for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The donor lungs must be considered 'marginal' (not perfect) by standard criteria, such as low oxygen levels or older age of the donor.
- The donor must be over 18 years old.
- Donor lungs cannot have widespread solid areas (consolidations) on both sides.
- The donor cannot have had chest trauma or been drowned.
- If you are the patient receiving the transplant, you cannot be in the ICU on a breathing machine or ECMO, or be having a re-transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medical devices used to improve the condition of donor lungs before they are transplanted. It aims to see which device works better to make more lungs suitable for transplant, potentially helping more patients receive the lungs they need.
This study looks at using a heart–lung machine (ECMO) to reduce complications and deaths after a lung transplant. It focuses on people getting a lung transplant who have certain types of lung-vessel (pulmonary) pressure problems.
This study compares two ways of using a heart-lung machine (ECMO) during lung transplant surgery. The goal is to see if using ECMO only when needed works as well as using it for everyone. This could help reduce risks and improve recovery.
This trial tests a special machine that keeps donated livers healthy before they're transplanted. It aims to improve transplant success and help more people receive a liver.
This trial tests a new way to safely use donor lungs that carry the hepatitis B virus (HBV). It combines a special light treatment, ex-vivo lung perfusion (cleaning the lungs outside the body), and antiviral medicines to prevent infection in the recipient. If you are on the lung transplant list and have been vaccinated against hepatitis B, this study may help expand your donor options.
This trial tests a new way to preserve donated lungs before transplant to lower the risk of complications. It may help primary graft dysfunction, a serious lung problem after surgery.
Hear when a new Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.